{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-009140","form_type":"8-K","ticker":"CBIO","cik":"0001253689","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2024-06-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.632634+00:00","generated_at":"2026-06-01T04:32:56.120373+00:00","sec_items":["5.02"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"GlycoMimetics grants performance-based stock options to NEOs vesting on FDA approval of uproleselan","bullets":["CEO Harout Semerjian granted 521,250 shares; CFO Brian Hahn and CMO Edwin Rock each granted 187,500 shares.","Options have exercise price of $0.2589 per share and vest upon FDA approval of uproleselan for AML.","Awards are in addition to service-based options granted Jan 12, 2024 with exercise price of $3.11 per share.","Vesting is contingent on continued service through the FDA approval date."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-009140","json":"https://secwatch.observer/filing/0001558370-24-009140.json","markdown":"https://secwatch.observer/filing/0001558370-24-009140.md","text":"https://secwatch.observer/filing/0001558370-24-009140.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1253689/000155837024009140/0001558370-24-009140-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1253689/000155837024009140/glyc-20240610x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T04:32:56.120373+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}